Last updated on September 2017

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.


Brief description of study

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.

Detailed Study Description

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region. Subjects enrolled in this treatment protocol will receive oral continuous dosing with ibrutinib at the same dose and schedule they were receiving at the end of the respective parent study. Treatment may be continued as long as the subjects continue to derive benefit from treatment with ibrutinib until such time that ibrutinib becomes commercially available for the indication of the parent study. Clinical evaluations (including safety assessments) will be performed per local standard of care for each disease that was studied in the parent protocol. At each visit, all ongoing and new onset non-serious AEs leading to dose reduction or discontinuation, serious adverse events (SAEs), adverse events of special interest (AESI), pregnancy events, other malignancies, and special reporting situations will be recorded.

Clinical Study Identifier: NCT03229200

Contact Investigators or Research Sites near you

Start Over

Raul Mena

Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center
Burbank, CA United States
  Connect »

Robert Chen

City Of Hope National Medical Center
Duarte, CA United States
  Connect »

Sven DeVos

University of California Los Angeles (UCLA)
Los Angeles, CA United States
  Connect »

Shuo Ma

Northwestern University
Chicago, IL United States
  Connect »

Nalini Janakiraman

Henry Ford Health System
Detroit, MI United States
  Connect »

Regan Holdridge

TRIO - Comprehensive Cancer Centers of Nevada
Las Vegas, NV United States
  Connect »

Morton Coleman

Clinical Research Alliance
Lake Success, NY United States
  Connect »

Jacqueline C Barrientos

Northwell Health
New Hyde Park, NY United States
  Connect »

Lia Palomba

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Mark Knapp

Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center
Columbus, OH United States
  Connect »

William C Ehmann

Penn State Milton S. Hershey Medical Center
Hershey, PA United States
  Connect »

Nathan Fowler

University of Texas MD Anderson Cancer Center
Houston, TX United States
  Connect »

Drew Rasco

START - South Texas Accelerated Research Therapeutics, LLC
San Antonio, TX United States
  Connect »